Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 15/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74385 | 0.95 | AVPR1B (0.48) | AVPR1BSLC6A9CYP3A4PARP1 | |
| SCHEMBL75609 | 0.90 | AVPR1B (0.55) | AVPR1BCYP3A4 | |
| SCHEMBL74615 | 0.90 | AVPR1B (0.48) | AVPR1BSLC6A9CYP3A4 | |
| SCHEMBL75630 | 0.90 | AVPR1B (0.47) | AVPR1BSLC6A9CYP3A4 | |
| SCHEMBL75346 | 0.90 | AVPR1B (0.59) | AVPR1BSLC6A9GPR6CYP3A4 | |
| SCHEMBL74208 | 0.89 | AVPR1B (0.62) | AVPR1BCYP3A4 | |
| SCHEMBL76769 | 0.88 | AVPR1B (0.46) | AVPR1BSLC6A9CYP3A4 | |
| SCHEMBL4510731 | 0.87 | AVPR1B (0.45) | AVPR1BSLC6A9CYP3A4 | |
| SCHEMBL75165 | 0.86 | AVPR1B (0.48) | AVPR1BSLC6A9CYP3A4PARP1PARP2 | |
| SCHEMBL74740 | 0.86 | AVPR1B (0.45) | AVPR1BSLC6A9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | claimed |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885SLC6A9 2917/4885GPR6 2274/4885 |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885SLC6A9 2917/4885GPR6 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.